- Home
- IRIX
IRIX
IRIDEX Corporation
as of 03-09-2026 12:57pm EST
$1.23
$0.01
-0.80%
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 25.8M | IPO Year: | 1996 |
| Target Price: | N/A | AVG Volume (30 days): | 42.8K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.25 | EPS Growth: | 8.47 |
| 52 Week Low/High: | $0.78 - $1.65 | Next Earning Date: | 04-01-2026 |
| Revenue: | $41,593,000 | Revenue Growth: | -9.89% |
| Revenue Growth (this year): | 9.61% | Revenue Growth (next year): | 8.12% |
| P/E Ratio: | -4.96 | Index: | N/A |
| Free Cash Flow: | -7298000.0 | FCF Growth: | N/A |
Stock Insider Trading Activity of IRIDEX Corporation (IRIX)
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Feb 17, 2026
Avg Cost/Share
$1.34
Shares
2,200
Total Value
$2,942.00
Owned After
118,690
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Feb 12, 2026
Avg Cost/Share
$1.43
Shares
1,500
Total Value
$2,145.00
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Feb 10, 2026
Avg Cost/Share
$1.46
Shares
1,000
Total Value
$1,460.00
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Feb 3, 2026
Avg Cost/Share
$1.38
Shares
2,500
Total Value
$3,450.00
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Jan 29, 2026
Avg Cost/Share
$1.44
Shares
1,101
Total Value
$1,587.64
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Jan 28, 2026
Avg Cost/Share
$1.46
Shares
1,300
Total Value
$1,898.00
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Jan 27, 2026
Avg Cost/Share
$1.48
Shares
3,385
Total Value
$5,009.46
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Jan 26, 2026
Avg Cost/Share
$1.52
Shares
1,243
Total Value
$1,889.36
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Jan 23, 2026
Avg Cost/Share
$1.48
Shares
5,221
Total Value
$7,716.12
Owned After
118,690
SEC Form 4
Dizon Romeo R
Buy
Chief Financial Officer
IRIX Jan 21, 2026
Avg Cost/Share
$1.51
Shares
2,159
Total Value
$3,233.27
Owned After
118,690
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Dizon Romeo R | IRIX | Chief Financial Officer | Feb 17, 2026 | Buy | $1.34 | 2,200 | $2,942.00 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Feb 12, 2026 | Buy | $1.43 | 1,500 | $2,145.00 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Feb 10, 2026 | Buy | $1.46 | 1,000 | $1,460.00 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Feb 3, 2026 | Buy | $1.38 | 2,500 | $3,450.00 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jan 29, 2026 | Buy | $1.44 | 1,101 | $1,587.64 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jan 28, 2026 | Buy | $1.46 | 1,300 | $1,898.00 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jan 27, 2026 | Buy | $1.48 | 3,385 | $5,009.46 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jan 26, 2026 | Buy | $1.52 | 1,243 | $1,889.36 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jan 23, 2026 | Buy | $1.48 | 5,221 | $7,716.12 | 118,690 | |
| Dizon Romeo R | IRIX | Chief Financial Officer | Jan 21, 2026 | Buy | $1.51 | 2,159 | $3,233.27 | 118,690 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 12, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 12, 2026 · 100% conf.
AI Prediction SELL
1D
-7.65%
$1.37
5D
-10.65%
$1.32
20D
-8.23%
$1.36
Price: $1.48 Prob +5D: 0% AUC: 1.000
0001193125-26-009912
8-K
0001006045false00010060452026-01-122026-01-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
January 12, 2026
Date of Report (date of earliest event reported)
IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
000-27598
77-0210467
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification Number)
1212 Terra Bella Avenue Mountain View, California 94043
(Address of principal executive offices, including zip code)
(650) 940-4700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Class
Trading Symbol
Name of Exchange on Which Registered
Common Stock, par value $0.01 per share
IRIX
Nasdaq Capital Market
Item 2.02. Results of Operations and Financial Condition.
On January 12, 2026, IRIDEX Corporation (the "Company") announced its preliminary, unaudited operational and financial results for its fourth fiscal quarter and full fiscal year ended January 3, 2026. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
99.1
Press Release dated January 12, 2026.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IRIDEX CORPORATION
By:
/s/ Patrick Mercer
Patrick Mercer
Chief Executive Officer
Date: January 12, 2026
-3-
2025 Q3 Q3 2025 Earnings
8-K Nov 12, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 12, 2025
0001193125-25-277598
8-K
false000100604500010060452025-11-112025-11-11
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
November 11, 2025
(Date of Report (date of earliest event reported)
IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
000-27598
77-0210467
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification Number)
1212 Terra Bella Avenue Mountain View, California 94043
(Address of principal executive offices, including zip code)
(650) 940-4700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Class
Trading Symbol
Name of Exchange on Which Registered
Common Stock, par value $0.01 per share
IRIX
Nasdaq Capital Market
Item 2.02. Results of Operations and Financial Condition.
On November 11, 2025, IRIDEX Corporation issued a press release discussing its financial results for its third fiscal quarter ended September 27, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
99.1
Press Release dated November 11, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IRIDEX CORPORATION
By:
/s/PATRICK MERCER
Patrick Mercer
Chief Executive Officer
Date: November 12, 2025
-3-
2025 Q2 Q2 2025 Earnings
8-K Aug 12, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 12, 2025
0000950170-25-107345
8-K
false000100604500010060452025-08-122025-08-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
August 12, 2025
(Date of Report (date of earliest event reported)
IRIDEX CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
000-27598
77-0210467
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification Number)
1212 Terra Bella Avenue Mountain View, California 94043
(Address of principal executive offices, including zip code)
(650) 940-4700
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Class
Trading Symbol
Name of Exchange on Which Registered
Common Stock, par value $0.01 per share
IRIX
Nasdaq Capital Market
Item 2.02. Results of Operations and Financial Condition.
On August 12, 2025, IRIDEX Corporation issued a press release discussing its financial results for its second fiscal quarter ended June 28, 2025. The press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.
This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
Description
99.1
Press Release dated August 12, 2025.
104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IRIDEX CORPORATION
By:
/s/PATRICK MERCER
Patrick Mercer
Chief Executive Officer
Date: August 12, 2025
-3-
Latest IRIDEX Corporation News
IRIX Breaking Stock News: Dive into IRIX Ticker-Specific Updates for Smart Investing
Compare IRIX vs Leading Stocks
See how IRIX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "IRIX IRIDEX Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.